期刊文献+

索利那新对预防前列腺切除术后尿急和急迫性尿失禁的作用 被引量:6

下载PDF
导出
摘要 下尿路症状(lower urinary tract symptoms,LUTS)在老年男性中十分常见。近期研究表明,至少有30%的60周岁以上男性有该征候群表现。而BPH在60周岁以上男性中发病率约为50%,并被认为是LUTS最常见的原因。约8%的BPH患者在药物治疗失败后选择手术以解除下尿路梗阻症状[1]。尽管已有许多研究证实了耻骨上和经尿道前列腺切除术的有效性和安全性,但是尿急和急迫性尿失禁等症状仍常出现于术后的患者。约有15%~36%的患者在术后拔除导尿管后出现了尿急甚至急迫性尿失禁,症状持续数周到数月不等[2]。我们研究的目的就在于探讨高选择性胆碱能受体(M3)阻滞剂索利那新,对治疗BPH患者在前列腺切除术后拔除导尿管后出现的尿急和急迫性尿失禁的效果。
出处 《中华男科学杂志》 CAS CSCD 2014年第7期663-665,共3页 National Journal of Andrology
  • 相关文献

参考文献12

  • 1Mitmpoulos D, Papadoukakis S, Zervas A, et al. Efficacy of toltero- dine in preventing urge incontinence immediately after prostatectomy. Int Urol Nephrol, 2006, 38(2) : 263-268.
  • 2Tubaro A, Carter S, Hind A, et al. A prospective study of the safety and efficacy of suprapubic transvesical prostatectomy in pa- tients with benign prostatic hyperplasia. J Urol, 2001, 166( 1 ) : 172-176.
  • 3程文 ,葛京平 ,周四维 ,高建平 .膀胱过度活动的药物治疗进展[J].医学研究生学报,2004,17(2):167-168. 被引量:4
  • 4Chapple CR, Van Kerrebroeck PE, Junemann KP, et al. Comparison of fesoterodine and toherodine in patients with overactive bladder. BJU Int, 2008, 102(9): 1128-1132.
  • 5Lam S, Hilas O. Pharmacologic management of overactive blad- der. Clin Interv Aging, 2007, 2(3) : 337-345.
  • 6Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int, 2007, 100(5) : 987-1006.
  • 7Chughtai B, Lee R, Sandhu J, et al. Conservative treatment for postprostatectomy incontinence. Rev Urol, 2013, 15 ( 2 ) : 61- 66.
  • 8Kaplan SA, He W, Kohun WD, et al. Solifenacin plus tamsulo- sin combination treatment in men with lower urinary tract symp- toms and bladder outlet obstruction: A randomized controlled trial. Eur Urol, 2013, 63(1) : 158-165.
  • 9Ohtake A, Ukai M, Hatanaka T, et al. In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur J Pharmacol, 2004, 492 (2-3) : 243-250.
  • 10Sussman DO. Overactive bladder: Treatment options in primary care medicine. J Am Osteopath Assoc, 2007, 107 ( 9 ) : 379- 385.

二级参考文献12

  • 1[1]Chancellor MB, De Groat WC. Intravesical capsaicin and resiniferatoxin therapy: spicing up the ways that we treat the overactive bladder[J].J Urol ,1999,162(1): 3-11.
  • 2[2]Larsson G, Hallen B, Nilvebrandt L. Tolterodine in the tretment of overative ldder : an analysis of the pooled phase Ⅱefficacy and safety data[J]. Urology,1999,53(5):990-990.
  • 3[3]Gupta SK, Sathyan G. Pharmacokinetics of an oral once a day controlled release oxybutnin formulation compared with immediate release oxybutnin[J]. J Clin Pharmacol,1999,39(3):289-296.
  • 4[4]Chancellor MB, Appell RA , Sathyan G et al. Effect of controlled release oxybutynin and tolterodine on salivary output[J]. Neurourol Urodyn, 2000,19(1):94.
  • 5[5]Frolich G, Burmeister S, Wiedemann A et al. Intravesical trospium chloride , oxybutynin, and verapimil for relaxation of detrusor muscle: placebo controlled, randomized clinical tial in Germany[J]. Arzneimittelforschung,1998,48(4):486-491.
  • 6[6]Rosario DJ, Cutinha PE, Chapple CR et al. The effects of ingle dose darifenicin on cystometric parameters and salivary flow in patients with urge incontinence secondary to detrusor instability[J].Eur Urol,1996,30(3):240.
  • 7[7]Phelan MW, Yoshimura N, Goins WF et al. Nerve growth factor(NGF) gene therapy improves rat diabetic cystopathy, but does not increase pain sensation[J]. J Urol,2000,163(3):245-248.
  • 8[8]Palmer LS, Zebold K, Firlt CF et al. Complications Of intravesical oxybutnin chloride therapy in the peditric myelomeningocele population[J]. J Urol,1997,157(2):638-640.
  • 9[9]Singh SS, Smith KM, Brown DM. Drug retention following intravesical delievery of fluorouracil therapeutic adhesive in C3H mouse bladderc[J]. Anticancer Drugs,1996,7(4):507-511.
  • 10[10]Dasgupta P, Chandiramani V, Parkinson MC et al. Treating the human bladder with capsaicin : isit safe?[J] Eur Urol,1998,33(1):28-32.

共引文献3

同被引文献72

  • 1张平,王秀华.老年尿失禁患者的心理状况[J].中国老年学杂志,2014,34(2):558-560. 被引量:32
  • 2Giuliano F,iickert S, Maggi M, et al. The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia [J]. Eur Urol,2013,63 (3) :506-516.
  • 3Kang M, Kim M, Choo MS, et al. Association of high bladder neck elevation with urodynamic bladder outlet obstruction in patients with lower urinary tract symptoms and benign prostatic hyperplasia[ J ]. Urology ,2014.84 (6) : 1461-1466.
  • 4Ahmed AF, Maarouf A, Shalaby E, et al. The impact of adding low-dose oral desmopressin therapy to tamsulosin therapy for treatment of nocturia owing to benign prostatic hyperplasia [ J]. World J Uro1,2015,33 (5) :649-657.
  • 5Madersbacber S, Marszalek M, Lackner J, et al. The long-term outcome of medical therapy for BPH [ J ]. Eur Urol, 2007,51 (6) :1522-1533.
  • 6Gacci M, Novara G, DeNunzio C, et al. Tolterodine extended release in the treatment of male OAB/storage LUTS: a system- atic review[ J]. J BMC Urol,2014,14:84.
  • 7Dimitmpoulos K, Gravas S. Solifenacin/tamsulosinfixed-dose combination therapy to treaflower urinary tract symptomsin pa- tients with benign prostatic hyperplasia [J]. Drug Des Devel T- her,2015,19(9) :1707-1716.
  • 8Chang DE, Te ALE, Staskin DR, et al. Efficacy and safety of tolterodine extended release and dutastefide in male overactive bladder patients with prostates > 30 grams[ J]. Urology ,2010, 75(5) :1144-1148.
  • 9Zlotta AR, Teillac P, Raynand P, et aL Evaluation of male sexual function in patients with lower unnary tract symptoms (LUTS) associated with benign prostatic hypcrptasia (BPH) treated with a pbytothcrapeutic agent ( pcrmixon), tarnsulosin or finasteride [ J]. Eur Uroi,2005,48 (2) :269-276.
  • 10Mittcrberger M, Pallwein L, Gradl J, et al. Persist entdemlsor over activity after transurcthral resection of the prostate is asso- ciatcd with reduced perfusion of the urinary bladder [ J ]. B/U Int,2007,99(4) :831-835.

引证文献6

二级引证文献67

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部